

Programm

2° Translational Science meeting Innsbruck

Hotel Austria-Trend Innsbruck

Thursday 15.11.2018

12.00 - 12.10 Introduction (W.Horninger, D.Wolf)

1) New avenues in therapy resistance (Z. Trajanoski, E.Gunsilius)

12.10 - 12.30 **The value of neutrophil-lymphocyte ratio in therapy resistance in renal cell cancer**

T. Klatter (Cambridge)

12.30 - 12.50 **Interaction of platelets and tumor microenvironment in therapy resistance**

V. Rolfes (Bonn)

12.50 - 13.10 **Molecular profiling as new source for therapy stratification**

A. Seeber (Innsbruck)

13.10 - 13.30 **Molecular mechanisms of therapy resistance in prostate cancer**

S. Duensing (Heidelberg)

13.30 - 13.50 **Functional Imaging/Immuno-PET: a new approach to predict resistance in uro-oncology?**

I. Virgolini (Innsbruck)

13.50 - 14.20 **Key note lecture: CTC/liquid biopsy/molecular subtyping in uro-oncology - how can pathologists help clinicians to guide treatment decisions?**

E. Comperat (Paris)

14.20 - 15.00 **Pause – Besuch der Industrieausstellung**

2) Targeting the tumor microenvironment (D. Wolf, A. Pircher)

15.00 - 15.20 **Major advances in Immunotherapy-resistance**

D. Wolf (Innsbruck)

New combination partners in Immuno-oncology

15.20 - 15.40 **Renal cell cancer**

M. Schmidinger (Wien)

15.40 - 16.00 **Non-muscle invasive bladder cancer**

W. Loidl (Linz)

16.00 - 16.20 **Muscle invasive bladder cancer**

A. Stenzl (Tübingen)

16.20 - 16.40	NSCLC G.Pall (Innsbruck)
16.40 - 17.00	The microbiome of the prostate tumor microenvironment W.Cazzaniga (Mailand)
17.00 - 17.30	Key note lecture: Tumor endothelial cells – a multi-omics approach G.Eelen (Leuven)
18.00	Gemeinsames Abendessen

Friday 16.11.2018

3) Hormonal and Chemotherapy (J.Bektic, A. Reissigl)

08.30 - 08.50	Biomarkers to investigate therapy resistance in prostate cancer H.Taubert (Erlangen)
08.50 - 09.10	The role of ARV 7 in therapy monitoring therapies in mCRPC M.Heck (München)
09.10 - 09.30	Imaging approaches to define therapy resistance in prostate cancer L. L. Lusuardi (Salzburg)
09.30 - 09.50	Treating mCRPC in light of new data in the mHSPC/M0 setting I.Tsaur (Mainz)
09.50 - 10.20	Key note lecture: Future and Promising approaches to overcome resistance in prostate cancer S. Joniau (Leuven)
10.20 - 10.45	Pause – Besuch der Industrieausstellung

4) Genetic defined cancers (W.Loidl, W.Horninger)

10.45-11.05	EGFR- NSCLC M. Filipits (Wien)
11.05 -11.25	BRCA Mutations- new therapeutic target and new hope for patients with mCRPC T. Bauernhofer (Graz)
11.25 -11.45	miR371a-3p- Testicular cancer K. Dieckmann (Hamburg)
11.45-12.05	VHL/TSC/Birt-Hogg-Dubé- Renal cell cancer M. Marszalek (Wien)
12.05-12.25	APOBEC3/FGFR- Bladder cancer M. Pichler (Graz)
12.25- 12.55	Key note lecture: Wilms tumor in children Ch. Radmayr (Innsbruck)
13.00 - 14.00	Mittagspause


5) Young investigators in Oncology (I. Heidegger, R. Pichler)

14.00 – 16.00 Presentation best abstracts

Award ceremony

Wir danken unseren Sponsoren:






Collaboration

Innovation

Education



2. Translational Science Meeting

Urology - Oncology - Resistance

15 & 16 November 2018 - Austria Trend Hotel - Innsbruck

www.translational-science-meeting.at